Product Information
RISPERDAL CONSTA 37.5 MG VIAL is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $950.4230 per EA under NDC 50458030711. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Oct 29, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458030711
Classification
Brand
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
New Drug (NDA)
FDA Application
NDA021346FDA Approved
10/29/2003
TE Code
AB
On Market Since
10/29/2003
Price Statistics
The NADAC for RISPERDAL CONSTA 37.5 MG VIAL has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 122.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $950.4230 per EA |
|---|---|
| All-time high | $956.6228 (May 13, 2026) |
| All-time low | $428.0082 (Nov 28, 2013) |
| 52-week high | $956.6228 |
| 52-week low | $928.6020 |
| Median price | $730.4260 |
| Average price | $713.5051 |
| Largest weekly change | +6.9% (Jan 16, 2019) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 67% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RISPERDAL CONSTA 37.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RISPERDAL CONSTA 37.5 MG VIAL, manufactured by Janssen Pharmaceuticals Inc., is $950.4230 per EA (NDC 50458030711), effective Aug 19, 2026.
How has the price of RISPERDAL CONSTA 37.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for RISPERDAL CONSTA 37.5 MG VIAL has risen 122.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RISPERDAL CONSTA 37.5 MG VIAL?
Since Nov 28, 2013, the NADAC for RISPERDAL CONSTA 37.5 MG VIAL has ranged from a low of $428.0082 (Nov 28, 2013) to a high of $956.6228 (May 13, 2026), with a median of $730.4260 per EA.
Are there cheaper alternatives to RISPERDAL CONSTA 37.5 MG VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISPERDAL CONSTA 12.5 MG VIAL, is $317.9314 per EA — about 67% below RISPERDAL CONSTA 37.5 MG VIAL.
Who manufactures RISPERDAL CONSTA 37.5 MG VIAL?
RISPERDAL CONSTA 37.5 MG VIAL (NDC 50458030711) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.